Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF© [PDF]
Orphanet Journal of Rare Diseases, 2021 Background Advanced systemic mastocytosis (AdvSM), indolent systemic mastocytosis (ISM), and smoldering systemic mastocytosis (SSM) are rare diseases characterized by neoplastic mast cell infiltration of more than one organ.
Fiona Taylor +9 more
doaj +2 more sources
The evaluation, management, and future of indolent systemic mastocytosis. [PDF]
Ann HematolIndolent systemic mastocytosis (ISM) is a chronic hematologic malignancy that has traditionally been managed primarily by allergists. However, with improved molecular diagnostics such as droplet digital PCR (ddPCR) for KIT D816V on bone marrow aspirate specimens and the availability of targeted therapies against KIT, hematologists are increasingly ...
Syal A, Toh J, McInerney A, Tremblay D.
europepmc +3 more sources
Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF©) and determination of a threshold score for moderate symptoms [PDF]
Orphanet Journal of Rare Diseases, 2023 Background The Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) (©Blueprint Medicines Corporation), a 12-item daily diary that assesses 11 signs and symptoms of indolent systemic mastocytosis (ISM) and smoldering systemic mastocytosis ...
Alan L. Shields +9 more
doaj +2 more sources
Primary cicatricial alopecia associated with systemic indolent mastocytosis [PDF]
JAAD Case Reports, 2020 We present a case of a 63-year-old woman diagnosed with indolent cutaneous and systemic mastocytosis (SM) who presented with hair loss due to primary cicatricial alopecia (PCA).
Sonya Prasad, BA +3 more
doaj +3 more sources
Indolent systemic mastocytosis mimicking Crohn's disease. [PDF]
Ann Gastroenterol, 2019 Mastocytosis is a rare and heterogeneous group of diseases whose common element is the presence of dense mast-cell infiltrates in various tissues. The gastrointestinal (GI) tract is frequently affected with vague and subtle manifestations, making the diagnosis of GI mastocytosis rather formidable and challenging. The diagnosis of the disease requires a
Hadjivasilis A +7 more
europepmc +4 more sources
Nemolizumab as an Alternative Therapeutic Option for Indolent Systemic Mastocytosis. [PDF]
CureusIndolent systemic mastocytosis (ISM) is a clonal mast cell disorder characterized by recurrent symptoms that can persist despite treatment with antihistamines, leukotriene antagonists, and mast cell stabilizers. Treatment options are limited when symptoms remain refractory, and avapritinib is contraindicated or declined.
Minbaeva S, Tyring SK.
europepmc +3 more sources
Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis
Haematologica, 2011 Systemic mastocytosis (SM) is a heterogeneous disorder characterized by the proliferation and accumulation of atypical mast cells (MC) in tissues, principally in the bone marrow (BM) and skin. The diagnosis of systemic mastocytosis requires the presence of multifocal dense mast cell infiltrates ...
Roberta Zanotti +9 more
doaj +4 more sources
Long-Term Successful Treatment of Indolent Systemic Mastocytosis With Omalizumab. [PDF]
Fed Pract, 2021 This case study suggests that omalizumab may help prevent anaphylaxis and reduce disease burden associated with systemic mastocytosis, but further studies and formal clinical trials are needed to confirm these findings.
Weiss SL, Hyman JB, Carlson GS, Coop CA.
europepmc +4 more sources
Venom immunotherapy in indolent systemic mastocytosis with high serum tryptase level [PDF]
Human Vaccines & Immunotherapeutics, 2021 Mastocytosis is a rare group of disorders characterized by abnormal accumulation of mast cells in the skin, bone marrow, and internal organs. In particular, patients with systemic mastocytosis are at an increased risk of frequent and severe episodes of ...
Ali Selcuk, Abdullah Baysan
doaj +2 more sources
Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical study [PDF]
Orphanet Journal of Rare Diseases, 2021 Background Indolent systemic mastocytosis (ISM) is a rare, clonal mast cell neoplasm characterized by severe, unpredictable symptoms. The Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) items compose a Total Symptom Score (TSS ...
Brad Padilla +10 more
doaj +2 more sources